Skip to content

Magnet stimulation therapy in idiopathic small fiber neuropathy patients

Magnet stimulation therapy in idiopathic small fiber neuropathy patients - MAGIC-SFN

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00033332
Enrollment
50
Registered
2024-05-31
Start date
2024-06-03
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Small fiber neuropathy with neuropathic pain

Interventions

Group 1: Repetitive magnetic stimulation of the M1 area on the left Group 2: Repetitive magnetic stimulation of the DLPFC area on the left

Sponsors

Uniklinik der RWTH Aachen
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Clinically confirmed small fiber neuropathy 2. Neuropathic pain as the lead symptom of SFN 3. No underlying acquired origin of nerve damage 4. Written informed consent prior to project participation 5. The subject is willing and able to follow the procedures outlined in the project plan

Exclusion criteria

Exclusion criteria: 1. Minority <18 years of age 2. Pregnancy and breastfeeding 3. Known epilepsy or epileptic seizure in the past 4. Serious brain disease (e.g. hydrocephalus, brain tumor) or serious head injury (traumatic brain injury) in the past or present 5. Other serious or unstable illness (e.g. asthma, coronary artery disease) that requires, for example, the wearing of electrical devices (e.g. pacemaker, drug pump) or metal parts (e.g. screws after bone fracture) in or on the body 6. Large tattoos that might interact with the magnetic field 7. Persons who are placed in an institution by court or official order 8. People who are unwilling or unable to understand and follow the instructions of the study 9. People who are incapable of giving consent and/or are unable to understand the nature, significance, and scope of the research project and to give their consent in writing

Design outcomes

Primary

MeasureTime frame
Pain reduction (NRS) by 30% compared to baseline

Secondary

MeasureTime frame
- Correlation of pain scores with depression markers - Comparison of two different stimulation localizations - Stratification of patients who may or may not respond to rTMS based on phenotype markers

Countries

Germany

Contacts

Public ContactMaike Dohrn

Uniklinik der RWTH Aachen

mdohrn@ukaachen.de0049241800

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026